Literature DB >> 9780162

The regulation of CD95 ligand expression and function in CTL.

J H Li1, D Rosen, D Ronen, C K Behrens, P H Krammer, W R Clark, G Berke.   

Abstract

Previous studies with CTL lines and CTL hybridomas have suggested that functional CD95 (APO-1/Fas)-ligand (CD95L) expression on effector CTLs is a consequence of specific CTL-target recognition and TCR triggering of newly transcribed CD95L. Such a control on the expression of CD95L could provide a double safeguard for killing only cognate target cells. Here the regulation of CD95L expression and function was tested in in vivo primed, alloreactive peritoneal exudate CTL (PEL) from perforin-deficient (P0) mice. CD95L-based, PEL-mediated cytotoxicity was blocked by brefeldin A, an inhibitor of intracellular protein transport, but not by the protein synthesis inhibitor emetine, the immunosuppressive drug cyclosporin A, or the DNA transcription inhibitor actinomycin D. CD95L mRNA transcripts in freshly isolated PEL were shown by RT-PCR; CD95L surface expression was evident by staining with Fas-Fc as well as CD95L Abs. Undiminished CD95L expression and cytocidal activity were found in PEL incubated for 48 h in culture, without adding Ag, mitogen, or cytokines. PEL expressed functional CD95L, yet exhibited target cell-specific killing, except when encountering high CD95-expressing cells. The results indicate that PEL use CD95L probably expressed in the Golgi and/or on the cell surface and do not require newly transcribed CD95L upon target cell conjugation. Hence the TCR-triggered recruitment of preformed CD95L, rather than its biosynthesis, controls CD95L-based specific lysis induced by CTL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9780162

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Induction of autoreactive CD8+ cytotoxic T cells during Theiler's murine encephalomyelitis virus infection: implications for autoimmunity.

Authors:  Ikuo Tsunoda; Li-Qing Kuang; Robert S Fujinami
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 2.  Cytotoxic immunological synapses.

Authors:  Michael L Dustin; Eric O Long
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

3.  Cytotoxic T lymphocyte perforin and Fas ligand working in concert even when Fas ligand lytic action is still not detectable.

Authors:  David Hassin; Orit G Garber; Avihai Meiraz; Yael S Schiffenbauer; Gideon Berke
Journal:  Immunology       Date:  2011-03-29       Impact factor: 7.397

4.  Testicular FasL is expressed by sperm cells.

Authors:  A D'Alessio; A Riccioli; P Lauretti; F Padula; B Muciaccia; P De Cesaris; A Filippini; S Nagata; E Ziparo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

5.  Initiation of alcoholic fatty liver and hepatic inflammation with a specific recall immune response in alcohol-consuming C57Bl/6 mice.

Authors:  I I Slukvin; P J Boor; T R Jerrells
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

6.  Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells.

Authors:  Jie-Hui Li; Dalia Rosen; Paul Sondel; Gideon Berke
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

7.  The contribution of the Fas/FasL apoptotic pathway in ulcer formation during Leishmania major-induced cutaneous Leishmaniasis.

Authors:  Liv Eidsmo; Susanne Nylen; Ali Khamesipour; Mari-Anne Hedblad; Francesca Chiodi; Hannah Akuffo
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

8.  In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.

Authors:  Zachary S Morris; Emily I Guy; David M Francis; Monica M Gressett; Lauryn R Werner; Lakeesha L Carmichael; Richard K Yang; Eric A Armstrong; Shyhmin Huang; Fariba Navid; Stephen D Gillies; Alan Korman; Jacquelyn A Hank; Alexander L Rakhmilevich; Paul M Harari; Paul M Sondel
Journal:  Cancer Res       Date:  2016-05-06       Impact factor: 12.701

9.  Increasing a robust antigen-specific cytotoxic T lymphocyte response by FMDV DNA vaccination with IL-9 expressing construct.

Authors:  Qiang Zou; Bing Wu; Xiaodan He; Yizhi Zhang; Youmin Kang; Jin Jin; Hanqian Xu; Hu Liu; Bin Wang
Journal:  J Biomed Biotechnol       Date:  2010-04-27

10.  Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors.

Authors:  German G Gomez; Susana B Read; Lazaro E Gerschenson; Daniela Santoli; Adam Zweifach; Carol A Kruse
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.